REGN
equitynet sellingRegeneron Pharmaceuticals Inc · NASDAQ NMS - GLOBAL MARKET
Buy it with play money
Fills at the latest stored close and lands in your paper portfolio
Sign in to buy REGN with $10,000 of play money and watch it from here.
Sign in to tradePrice, and when Congress traded it
Hollow marks where they traded, filled where the filing went public
Hover a marker to see who traded and what it was worth.
If you had bought it yourself
Paid at that day's close, held ever since. No member involved.
Working it out…
Financials
As each period's own 10-K or 10-Q reported it
At the $746.54 close on Oct 9, 2026, against 106M shares and the balance sheet at Jun 30, 2026; earnings, sales and cash flow over the four quarters to Jun 30, 2026. A ratio is left out where its denominator is not positive. Fair value is the company's own median P/E, price to sales and price to free cash flow at its last ten fiscal year ends, applied to its trailing figures, the middle of the three: its valuation against its own past, not against its growth or its rivals.
| Line item | FY 2016 Dec 31, 2016 | FY 2017 Dec 31, 2017 | FY 2018 Dec 31, 2018 | FY 2019 Dec 31, 2019 | FY 2020 Dec 31, 2020 | FY 2021 Dec 31, 2021 | FY 2022 Dec 31, 2022 | FY 2023 Dec 31, 2023 | FY 2024 Dec 31, 2024 | FY 2025 Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9B | $5.9B | $6.7B | $7.9B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Gross margin | 96.0% | 96.5% | 96.5% | 94.9% | — | — | — | — | — | — |
| Operating income | $1.3B | $2.1B | $2.5B | $2.2B | $3.6B | $8.9B | $4.7B | $4B | $4B | $3.6B |
| Operating margin | 27.4% | 35.4% | 37.8% | 28.1% | 42.1% | 55.7% | 38.9% | 30.9% | 28.1% | 24.9% |
| Net income | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4B | $4.4B | $4.5B |
| Net margin | 18.4% | 20.4% | 36.4% | 26.9% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
| EPS (diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Operating cash flow | $1.5B | $1.3B | $2.2B | $2.4B | $2.6B | $7.1B | $5B | $4.6B | $4.4B | $5B |
| Capital spending | $511.9M | $272.6M | $383.1M | $429.6M | $614.6M | $551.9M | $590.1M | $718.6M | $755.9M | $898.4M |
| Free cash flow | $961.5M | $1B | $1.8B | $2B | $2B | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B |
| Buybacks | $0 | $0 | $4.4M | $275.9M | $5.8B | $1.6B | $2.1B | $2.2B | $2.6B | $3.4B |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $370.3M |
| Cash | $535.2M | $812.7M | $1.5B | $1.6B | $2.2B | $2.9B | $3.1B | $2.7B | $2.5B | $3.1B |
| Debt | — | — | — | $0 | $2B | $2B | $2B | $2B | $2B | $2B |
| Shareholders' equity | $4.4B | $6.1B | $8.8B | $11.1B | $11B | $18.8B | $22.7B | $26B | $29.4B | $31.3B |
| Shares outstanding | — | — | — | — | — | — | — | — | — | — |
Figures come from the company's XBRL filings as the SEC publishes them. Quarters are worked out from year-to-date figures, and a fourth quarter is the year less its first nine months, which is why it has no EPS: per-share figures do not subtract. Earlier years are on today's share basis where a split has happened since. A later restatement is not mixed into a year it was never applied to, so where a 10-K restated the year before — a business sold, say — that year's fourth quarter is left blank rather than worked out across two bases. A dash means the company did not report that line under a standard tag for that period. Every filing on EDGAR.
Short interest
Shares sold short, as brokers report them to FINRA twice a month
| Settlement date | Shares short | Change | Days to cover |
|---|---|---|---|
| Sep 30, 2026 | 2.15M | -14.9% | 2.5 |
| Sep 15, 2026 | 2.53M | -1.0% | 4.4 |
| Aug 31, 2026 | 2.55M | +6.5% | 3.9 |
| Aug 14, 2026 | 2.4M | -29.2% | 3.1 |
| Jul 31, 2026 | 3.39M | -3.3% | 3.9 |
| Jul 15, 2026 | 3.5M | +0.2% | 4.7 |
| Jun 30, 2026 | 3.49M | +5.8% | 2.9 |
| Jun 15, 2026 | 3.3M | +10.1% | 3.4 |
Largest fails to deliver, the last year
38 settlement days with at least $10,000 of shares sold and not delivered
| Settlement date | Shares | Value |
|---|---|---|
| Feb 4, 2026 | 3.89K | $3M |
| Aug 18, 2026 | 2.02K | $1.6M |
| Sep 3, 2026 | 1.56K | $1.3M |
| Aug 10, 2026 | 1.44K | $1.1M |
| Jul 31, 2026 | 1.28K | $942.1K |
Short interest is every broker's short position at the settlement date, reported to FINRA and published about a week and a half later; it does not say who is short. Days to cover is the short position over the average day's trading, and the share of the company is against the shares outstanding on its latest filing. A fail to deliver is the balance of shares sold and not delivered by settlement, from the SEC: it can be a short seller who never borrowed the stock, but is as often a late delivery that clears within days.
What they lobby on
Disclosed to the Senate, largest spend first
- REGENERON PHARMACEUTICALS, INC$640K
Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign), Taxation/Internal Revenue Code
1st Quarter (Jan 1 - Mar 31) 2026
- REGENERON PHARMACEUTICALS, INC$630K
Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign), Taxation/Internal Revenue Code
2nd Quarter (Apr 1 - June 30) 2026
- BGR GOVERNMENT AFFAIRS$90K
Health Issues
1st Quarter (Jan 1 - Mar 31) 2026
- BGR GOVERNMENT AFFAIRS$90K
Health Issues
2nd Quarter (Apr 1 - June 30) 2026
- CHECKMATE GOVERNMENT RELATIONS$90K
Health Issues
1st Quarter (Jan 1 - Mar 31) 2026
- CHECKMATE GOVERNMENT RELATIONS$90K
Health Issues
2nd Quarter (Apr 1 - June 30) 2026
- CRANE STRATEGIES$50K
Budget/Appropriations
1st Quarter (Jan 1 - Mar 31) 2026
- CRANE STRATEGIES$50K
Budget/Appropriations
2nd Quarter (Apr 1 - June 30) 2026
Federal contracts
Largest awards of the last two years
- Department of Health and Human Services$973.6M
REGENERON PHARMACEUTICALS INC · from Sep 30, 2017
- Department of Health and Human Services$278.8M
REGENERON PHARMACEUTICALS INC · from Sep 21, 2017
- Department of Health and Human Services$8.6M
REGENERON PHARMACEUTICALS INC · from Aug 9, 2016
More on REGN
Who traded it
Most active first
Every disclosure
53 in total, newest first
Follow Regeneron Pharmaceuticals Inc (REGN) by email
New trades in Regeneron Pharmaceuticals Inc (REGN) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.